Dalmevin / Dalmevin Plus

 

  #MCNews

 

Launch in IRAQ

Article: Mrs. Sarah Abdallah Salem, Product Manager - MENA 

Medochemie and its business partner Warba Scientific Drug Bureau held a very successful launch event in Iraq for the market introduction of Dalmevin (Vildagliptin) and Dalmevin plus (Vildagliptin/Metformin), its newest addition to the company’s rich portfolio on Anti-diabetes therapeutic area, in its constant determination to deliver affordable, high-quality products to people around the globe in a manner that supports sustainability.

The launch was held on 20^th of May in association with the 16^th International Scientific Conference organized by Al-Mustansiriyah College of Medicine where more than 150 Endocrinologists from public and private sector attended. They all had the opportunity to come across the latest scientific data available on the molecule while sharing experience from actual clinical practice.



The renowned Endocrinologist and Senior Consultant Dr. Haidar Fadhil; head of department of medicine at collage of Al-Mustansiriyah University, presented the up-to-date practices on Diabetes Mellitus management focusing on the efficacy, safety of Vildagliptin, and on how targets for patients with T2DM can timely and efficiently be achieved providing them with a better quality of life.

Medochemie vision in the upcoming 2-3 years is to increase the depth and breadth of medicine range to cover new multiple therapeutic areas to ensure broader reach.